<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Respir Med J</journal-id><journal-id journal-id-type="publisher-id">TORMJ</journal-id><journal-title>The Open Respiratory Medicine Journal</journal-title><issn pub-type="epub">1874-3064</issn><publisher><publisher-name>Bentham Science Publishers Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19340318</article-id><article-id pub-id-type="pmc">2606653</article-id><article-id pub-id-type="publisher-id">TORMJ-2-1</article-id><article-id pub-id-type="doi">10.2174/1874306400802010001</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Not All Children with Under-Control Asthma are Controlled</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ricci</surname><given-names>G</given-names></name><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Dondi</surname><given-names>A</given-names></name></contrib><contrib contrib-type="author"><name><surname>Calamelli</surname><given-names>E</given-names></name></contrib><contrib contrib-type="author"><name><surname>Dell&#x02019;Omo</surname><given-names>V</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pagliara</surname><given-names>L</given-names></name></contrib><contrib contrib-type="author"><name><surname>Belotti</surname><given-names>T</given-names></name></contrib><contrib contrib-type="author"><name><surname>Masi</surname><given-names>M</given-names></name></contrib></contrib-group><aff id="aff">Department of Paediatrics, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy</aff><author-notes><corresp id="cor1"><label>*</label>Address correspondence to this author at the Department of Paediatrics, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy; E-mail: <email xlink:href="giampaolo.ricci@unibo.it">giampaolo.ricci@unibo.it</email></corresp></author-notes><pub-date pub-type="epub"><day>6</day><month>2</month><year>2008</year></pub-date><pub-date pub-type="collection"><year>2008</year></pub-date><volume>2</volume><fpage>1</fpage><lpage>6</lpage><history><date date-type="received"><day>10</day><month>1</month><year>2008</year></date><date date-type="rev-recd"><day>16</day><month>1</month><year>2008</year></date><date date-type="accepted"><day>23</day><month>1</month><year>2008</year></date></history><permissions><copyright-statement>2008 Bentham Science Publishers Ltd.</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<uri xlink:type="simple" xlink:href="http://creativecommons.org/licenses/by/2.5/">http://creativecommons.org/licenses/by/2.5/</uri>), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>Subclinical lung function alterations can sometimes be discovered in asthmatic patients under clinical control. This study aimed to identify the burden of asthmatic children with subclinical airways abnormalities who may benefit from an adjustment in asthma therapy. 134 6-to-17-year-old asthmatic children were enrolled. Of them, 98 presented apparently under clinical control disease and all performed spirometry before and after bronchodilation: 17 (17.3%) had a positive bronchodilation test, in addition to significantly lower lung function indexes as compared to those with under-control asthma who had a negative bronchodilation test. These patients were randomized and re-evaluated: patients (n=8) receiving an adjustment in their therapy showed an improvement in lung function tests and quality of life indexes as compared to 7 without therapy adjustment. In conclusion, a substantial number of apparently-under-control asthmatic children show airways alterations that can be improved by adjusting their therapy, which also seems to enhance their quality of life.</p></abstract><kwd-group><title>Keywords</title><kwd>Asthma control</kwd><kwd>bronchodilation test</kwd><kwd>childhood asthma</kwd><kwd>lung function</kwd><kwd>spirometry.</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Asthma is the most frequent chronic disease in childhood and its prevalence is increasing [<xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R2">2</xref>], but only a part of the patients reach the goals of control set out by the Global Initiative for Asthma (GINA) [<xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R4">4</xref>]. Adequate therapy may limit bronchial inflammation, thus improving the health status of the asthmatic child and preventing the disease severity from worsening [<xref ref-type="bibr" rid="R3">3</xref>]. The more severe asthma is in childhood, the more likely it is that the disease will persist in adulthood [<xref ref-type="bibr" rid="R5">5</xref>]. The main goal to be achieved in the management of the asthmatic child is to obtain a control both of the symptoms and of subtle airways alterations that can only be revealed by laboratory exams.</p><p>Lung function testing and the measurement of bronchodilation responsiveness are recommended for the diagnosis of asthma and for its monitoring over time [<xref ref-type="bibr" rid="R3">3</xref>]. The post-bronchodilation forced expiratory volume at the first second (FEV<sub>1</sub>) measures the best lung function that can be achieved by bronchodilator therapy on the day of the visit [<xref ref-type="bibr" rid="R6">6</xref>]; a suboptimal post-bronchodilation FEV<sub>1</sub> indicates bronchial obstruction.</p><p>Several studies confirm that lung function can be altered even in patients whose disease is judged to be under control according to their symptoms referral and the use of reliever medications [<xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R7">7</xref>,<xref ref-type="bibr" rid="R9">9</xref>]. Collecting symptoms from the children or their parents can though be troublesome. A non-recognition of the symptoms can lead to an underestimation of the severity of asthma, consequently to inappropriate treatment, and eventually to a worsening of the disease severity.</p><p>It seems that taking into account only the symptoms as referred by the children or their parents in order to judge asthma control is insufficient [<xref ref-type="bibr" rid="R7">7</xref>-<xref ref-type="bibr" rid="R9">9</xref>]. The present study aimed to demonstrate the usefulness of performing spirometry and the bronchodilation test in asthmatic children during routine clinical visits in order to monitor their actual asthma control and severity.</p></sec><sec sec-type="materials|methodology"><title>MATERIALS AND METHODOLOGY</title><sec><title>Patients</title><p>134 children (98 males) aged 6 to 17, who had been consecutively referred to the Allergology. Outpatient section of our clinic between November 2005 and October 2006, were included, all having a diagnosis of allergic asthma which had been established previously.</p><p>All the patients underwent a clinical examination to assess their asthma severity according to the GINA guidelines [<xref ref-type="bibr" rid="R3">3</xref>], and the status of asthma control on the basis of the parameters suggested by the Joint Task Force on Practice Parameters for Allergy and Immunology [<xref ref-type="bibr" rid="R10">10</xref>]. A child was considered to be clinically under control if, in the previous two weeks, there had been: 1) asthma symptoms twice a week or less; 2) rescue bronchodilator use twice a week or less; 3) no nighttime or early morning awakening; 4) no limitations on exercise, work, school; 5) well-controlled asthma by patient and physician assessment; 6) normal or personal best FEV<sub>1</sub>; 7) absence of bronchospasm at auscultation. Therapy prior to the visit was recorded.</p></sec><sec><title>Lung Function Testing</title><p>All the patients performed a spirometry by means of a Multispiro SA/100 spirometer (Medical Equipment Designs, Laguna Hills, CA, USA). The best of a minimum of three recordings was chosen and a bronchodilation test was done by the administration of 200 mcg of dry salbutamol powder and repetition of the spirometry 15 minutes later. Spirometric indices were expressed as percentage of the predicted values (Polgar revisited) [<xref ref-type="bibr" rid="R11">11</xref>]. The result of the bronchodilation test was evaluated by examining the variation in FEV<sub>1</sub> before and after bronchodilation expressed as a percentage change relative to the baseline values (deltaFEV<sub>1</sub>): the test was considered positive when deltaFEV<sub>1</sub> was &#x02265;12% [<xref ref-type="bibr" rid="R7">7</xref>,<xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R13"> 13</xref>]. We chose the value of deltaFEV<sub>1</sub> &#x02265;12% instead of &#x02265;15% to increase the sensibility of the test.</p></sec><sec><title>Skin Prick Tests (SPT)</title><p>A Skin Prick Test was performed to establish possible sensitization to the main seasonal (grass pollens, <italic>Parietaria judaica</italic>) and perennial (<italic>Dermatophagoides farinae</italic>, <italic>Dermatophagoides pteronyssinus</italic>, <italic>Alternaria alternatae</italic>, cat and dog dander) allergens involved in allergic asthma (Lofarma, Milan, Italy).</p></sec><sec><title>Health-Related Quality of Life (HRQL)</title><p>Patients&#x02019; HRQL was measured by administering the Pediatric Asthma Quality of Life Questionnaire (PAQLQ) [<xref ref-type="bibr" rid="R14">14</xref>].</p></sec><sec><title>Statistical Analysis</title><p>Data were examined by means of SPSS 13.0 for Windows (SPSS/PC; SPSS Inc., Chicago, IL, USA). Student&#x02019;s t-test and linear regression were used. Results were considered significant for a p value &#x02264;0.05.</p></sec><sec><title>Ethical Consideration</title><p>This research was conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from parents before the children were included in the study.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>According to our parameters, the asthma was under control in 98 children (73.1%), but not in the remaining 36 (26.9%). Of the 98 children with controlled disease, 17 (17.3%) had a positive bronchodilation test, meaning a deltaFEV<sub>1</sub> &#x02265;12%. This allowed us to divide our population into three different groups, one including patients with their asthma under control and with a negative bronchodilation test, the second consisting of children with controlled asthma but a positive bronchodilation test and the third including patients with uncontrolled asthma. Table <bold><xref ref-type="table" rid="T1">1</xref></bold> describes the main clinical and functional characteristics of our population. Table <bold><xref ref-type="table" rid="T2">2</xref></bold> shows the results of spirometry, bronchodilation test, Skin Prick Test and PAQLQ scores.</p><p>Firstly, differences in spirometric data between different groups in our population were examined. Results of t-test showed that FEV<sub>1</sub> and the ratio between FEV<sub>1</sub> and the forced vital capacity (FVC) differed significantly (p&#x02264;0.001 and p&#x02264;0.005 respectively) between patients with apparently under control asthma (with a positive or negative response to the bronchodilation test) and patients with not-controlled asthma.</p><p>Moreover, FEV<sub>1</sub> and FEV<sub>1</sub>/FVC differed significantly (p&#x02264;0.05 and p&#x02264;0.01 respectively) between patients with asthma under control and a positive or negative response to the bronchodilation test. No significant differences were found in FVC between these groups. FEV<sub>1</sub> and FEV<sub>1</sub>/FVC were not significantly different (p=0.180 and p=0.785 respectively) between patients with asthma under control but a positive bronchodilation test and patients with uncontrolled asthma.</p><p>Analysis of the differences in HRQL between groups showed that PAQLQ scores were similar in all children with asthma under control independently of bronchodilation test results, but a statistically significant difference was found between the scores of children with controlled asthma and a positive bronchodilation test, and children with uncontrolled disease (p&#x02264;0.01).</p><p>Examination of the allergic condition in the population did not highlight differences between the three groups regarding positive Skin Prick Test to the main allergens involved in allergic asthma (Table <bold><xref ref-type="table" rid="T3">3</xref></bold>).</p><p>Patients showing a discrepancy between the results of spirometry and asthma control were proposed to be reevaluated after a few months in order to reassess their asthma control and lung function. These patients were randomized and divided in two groups: 8 children (first group) had an adjustment in their asthma therapy, consisting of the introduction of or increase in inhaled corticosteroids (ICS), which have been shown to provide an improvement in airway responsiveness and asthma control [<xref ref-type="bibr" rid="R15">15</xref>]. Remaining 9 children (second group) had no adjustment in their therapy. Two children of the second group missed the visit. Table <bold><xref ref-type="table" rid="T4">4</xref></bold> shows the spirometric values and PAQLQ scores in the two subgroups of patients at the first visit. No significant differences were found between the two groups.</p><p>Fifteen children were re-evaluated after 1 to 4 months, 8 of whom had had their therapy adjusted and 7 had not. Control of spirometry showed that 7 (87.5%) of the 8 children with a change in their therapy had a negative response to the bronchodilation test and 1 (12.5%) had a positive response, whereas among the patients with no change in asthma therapy 3 (42.9%) had a negative bronchodilation test, and the remaining 4 (57.1%) had an increase in FEV<sub>1</sub> after salbutamol &#x02265;12% (Fig. <bold><xref ref-type="fig" rid="F1">1</xref></bold>).</p><p>The same group of patients completed the PAQLQ again at the second visit. Median values showed an improvement in HRQL in those children who had been treated with ICS (6.48 at the first time, 6.72 at the second), and a worsening in children whose therapy had not been modified (6.73 and 6.39), but differences are not statistically significant. The examination of the subscales of the questionnaire indicates that 5 out of 8 children who had been treated with ICS had an improvement in the &#x0201c;activity limitations&#x0201d; domain, whereas only 2 out of 7 children who had not been treated with ICS showed this enhancement.</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The main goal in the management of the asthmatic child is to obtain control of the disease, but subclinical alterations can be occasionally revealed in the lung function of asthmatic patients under apparent clinical control. No specific guidelines could be found about the approach to this problem, even if several studies reported such discrepancies, and the fact that asthma control is poorly judged when symptoms alone are considered has already been stated [<xref ref-type="bibr" rid="R7">7</xref>,<xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R16">16</xref>-<xref ref-type="bibr" rid="R19">19</xref>].</p><p>Korhonen  in 1999 evaluated the treatment policy for asthmatic children in the area of Kuopio, Finland [<xref ref-type="bibr" rid="R8">8</xref>]. PEF, spirometry and bronchodilation test results were collected from 195 school-aged patients. 11% of them had a positive the bronchodilation test as the only sign of bronchial obstruction, pointing to inadequate therapy.</p><p>Our study shows a prevalence of 17.3% of positive bronchodilation tests in a group of asthmatic children who were in a symptom-free period, indicating an occult bronchial obstruction. The lung function of these children was more similar to that of children with uncontrolled asthma than to the one of those with controlled asthma and a negative bronchodilation test.</p><p>The reasons why these children are asymptomatic despite having pulmonary function impairment can be multiple. First of all, an underlying, but still subclinical, pathological process in the airways could be hypothesized, similarly to what happens in some patients with apparently outgrown disease [<xref ref-type="bibr" rid="R20">20</xref>-<xref ref-type="bibr" rid="R22">22</xref>]. Secondly, patients with asthma frequently have poor recognition or perception of their symptoms [<xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R22">22</xref>,<xref ref-type="bibr" rid="R23">23</xref>]. Boulet  [<xref ref-type="bibr" rid="R22">22</xref>] in 1994 showed that the perception of symptoms associated with airways obstruction follows a normal unimodal distribution in the population with asthma; there are some &#x0201c;hypoperceivers&#x0201d; who can be asymptomatic or have minimal symptoms even with marked reductions in expiratory flows. A poor sensibility of airways obstruction has been demonstrated when convalescing from an acute asthmatic attack, during regular follow-ups, during a stable state of asthma, and even during acute episodes [<xref ref-type="bibr" rid="R18">18</xref>,<xref ref-type="bibr" rid="R24">24</xref>-<xref ref-type="bibr" rid="R27">27</xref>]; some patients have difficulty in distinguishing asthmatic dyspnoea from exercise-induced physiological breathlessness [<xref ref-type="bibr" rid="R28">28</xref>]. Moreover, collecting the symptoms story from the parents can sometimes be misleading on the actual status because of the social and psychological impact of admitting having a child with asthma; collecting the symptoms report directly from the kids could be more accurate [<xref ref-type="bibr" rid="R29">29</xref>], even if children, and mainly adolescents [<xref ref-type="bibr" rid="R5">5</xref>], may deny symptoms.</p><p>We believe that patients with a positive response to the bronchodilation test even in the absence of symptoms should be regarded as undertreated. Our data on lung function after treatment (figure <xref ref-type="fig" rid="F1">1</xref>) show an improvement in most of the patients. On the contrary, 4 children out of 7, who were not treated after positive bronchodilation test, did not show an improvement in lung function at re-evaluation. The reason why more than 40% of children with unmodified therapy also showed an improvement in lung function can be imputed to the fact that a more stringent medical control often induces a patient&#x02019;s better compliance to therapy and disease management.</p><p>The administration of the PAQLQ did not reveal any differences in HRQL between children with under-control asthma but a different response to bronchodilation. All of them, however, had a significantly better HRQL than children with uncontrolled disease. Although HRQL evaluation does not help to identify patients in need of further therapy, it is interesting to note that controlled patients with a positive bronchodilation test have some characteristics (asthma control, HRQL) in common with those well controlled and not respondent to bronchodilation, while they are more similar to uncontrolled children for other features (lung function).</p><p>However, PAQLQ re-administration in the 15 children who repeated spirometry because of the discrepancy between clinical and functional data indicates an improvement in HRQL in those who underwent ICS therapy or had an augmentation in the dosage. Their activity limitations seem to be the most concerned, because 5 children out of 8 improved in this domain of the questionnaire.</p><p>The first studies which identified such discrepancies between lung function and clinical control were conducted 20 to 30 years ago. Even if since then new drugs have been developed, asthma has been widely studied and its diagnosis and treatment have generally improved, the point of asymptomatic airways alterations is still up-to-date. Adequate treatment prevents pulmonary function from worsening: in persistent asthma, ICS suppress airway inflammation, reduce airway hyperresponsiveness, improve asthma control and prevent symptoms [<xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R15">15</xref>]. Persistent abnormal lung function in childhood, measured either at baseline or after bronchodilation, is probably associated with more severe asthma and an unfavourable prognosis [<xref ref-type="bibr" rid="R5">5</xref>]. The limitation of our study is that it does not include Exhaled Nitric Oxide measurements, which could add further informations on the inflammatory status and, therefore, on asthma control [<xref ref-type="bibr" rid="R30">30</xref>]. This device is very useful in clinical practice, but, by now, it is not still available in all pneumologic and allergologic center.</p><p>Undertreated patients are exposed to a worse progression of asthma severity and the bronchodilation test, even in the absence of Nitric Oxide measurements, seems to identify those children who are in need of a reassessment of their therapy. Moreover, our results indicate that the pharmacological treatment of an occult bronchial obstruction helps improving HRQL.</p></sec><sec sec-type="conclusion"><title>CONCLUSION</title><p>In conclusion, we believe that it is advisable to perform spirometry in asthmatic children in order to provide adequate therapy for their actual lung condition, which can be revealed by the bronchodilation test. Establishing asthma control solely on the basis of clinical parameters could be insufficient. In the absence of Nitric Oxide measurements, spirometry is a simple examination which is normally performable in every pneumologic or allergologic outpatient clinic and allows an evaluation of the bronchial obstruction status of the lung of the asthmatic school-aged child without any further, expensive investigation.</p></sec></body><back><glossary><title>ABBREVIATIONS</title><def-list><def-item><term id="A1">BD test</term><def><p>= Bronchodilation test</p></def></def-item><def-item><term id="A2">FEV<sub>1</sub></term><def><p>= Forced expiratory volume at the first second</p></def></def-item><def-item><term id="A3">FVC</term><def><p>= Forced vital capacity</p></def></def-item><def-item><term id="A4">HRQL</term><def><p>= Health-related quality of life</p></def></def-item><def-item><term id="A5">ICS</term><def><p>= Inhaled corticosteroids</p></def></def-item><def-item><term id="A6">LABA</term><def><p>= Long-acting &#x003b2;<sub>2</sub>agonists</p></def></def-item><def-item><term id="A7">PAQLQ</term><def><p>= Pediatric Asthma Quality of Life Questionnaire</p></def></def-item></def-list></glossary><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bousquet</surname><given-names>J</given-names></name><name><surname>Clark</surname><given-names>TJ</given-names></name><name><surname>Hurd</surname><given-names>S</given-names></name><etal/></person-group><article-title>GINA guidelines on asthma and beyond</article-title><source>Allergy</source><year>2007</year><month>2</month><volume>62</volume><issue>2</issue><fpage>102</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">17298416</pub-id></citation></ref><ref id="R2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weinmayr</surname><given-names>G</given-names></name><name><surname>Weiland</surname><given-names>SK</given-names></name><name><surname>Bj&#x000f6;rkst&#x000e9;n</surname><given-names>B</given-names></name><etal/></person-group><collab>ISAAC Phase Two Study Group</collab><article-title>Atopic sensitization and the international variation of asthma symptom prevalence in children</article-title><source>Am J Respir Crit Care Med</source><year>2007</year><volume>76</volume><issue>6</issue><fpage>565</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">17575099</pub-id></citation></ref><ref id="R3"><label>3</label><citation citation-type="web"><article-title>Global strategy for asthma management and prevention</article-title><source>GINA Report. Available from:<uri xlink:type="simple" xlink:href="http://www.ginasthma.com/guidelineitem.asp??">http://www.ginasthma.com/guidelineitem.asp??</uri></source><year>2006</year><access-date>Accessed 16 December 2006</access-date><comment>Revised 2006</comment></citation></ref><ref id="R4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gustafsson</surname><given-names>PM</given-names></name><name><surname>Watson</surname><given-names>L</given-names></name><name><surname>Davis</surname><given-names>KJ</given-names></name><name><surname>Rabe</surname><given-names>KF</given-names></name></person-group><article-title>Poor asthma control in children evidence from epidemiological surveys and implications for clinical practice</article-title><source>Int J Clin Pract</source><year>2006</year><volume>60</volume><fpage>321</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">16494648</pub-id></citation></ref><ref id="R5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roorda</surname><given-names>RJ</given-names></name></person-group><article-title>Prognostic factors for the outcome of childhood asthma in adolescence</article-title><source>Thorax</source><year>1996</year><volume>51 </volume><issue>Suppl 1</issue><fpage>S7</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">8658386</pub-id></citation></ref><ref id="R6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Enright</surname><given-names>PL</given-names></name><name><surname>Lobowitz</surname><given-names>MD</given-names></name><name><surname>Cockroft</surname><given-names>DW</given-names></name></person-group><article-title>Physiologic measures: pulmonary function tests.Asthma outcome</article-title><source> Am J Respir Crit Care Med</source><year>1994</year><volume>149 </volume><issue>2 Pt 2</issue><fpage>S9</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">8298772</pub-id></citation></ref><ref id="R7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Linna</surname><given-names>O</given-names></name></person-group><article-title>Spirometry bronchodilator test or symptom scoring for the assessment of childhood asthma</article-title><source>Acta Paedr</source><year>1996</year><volume>85</volume><fpage>564</fpage><lpage>9</lpage></citation></ref><ref id="R8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Korhonen</surname><given-names>K</given-names></name><name><surname>Korppi</surname><given-names>M</given-names></name><name><surname>Remes</surname><given-names>ST</given-names></name><name><surname>Reijonen</surname><given-names>TM</given-names></name><name><surname>Remes</surname><given-names>K</given-names></name></person-group><article-title>Lung function in school-aged asthmatic children with inhaled cromoglycate, nedocromil and corticosteroid therapy</article-title><source>Eur Respir J</source><year>1999</year><volume>13</volume><fpage>82</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">10836328</pub-id></citation></ref><ref id="R9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bridge</surname><given-names>PD</given-names></name><name><surname>McKenzie</surname><given-names>SA</given-names></name></person-group><article-title>Bronchodilator responsiveness testing in young children</article-title><source>Arch Dis Child</source><year>2001</year><volume>84</volume><fpage>525</fpage><pub-id pub-id-type="pmid">11372088</pub-id></citation></ref><ref id="R10"><label>10</label><citation citation-type="journal"><article-title>Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology and Joint Council of Allergy, Asthma and Immunology.Attaining optimal asthma control a practice parameter</article-title><source>J Allergy Clin Immunol</source><year>2005</year><volume>116</volume><fpage>S3</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">16334921</pub-id></citation></ref><ref id="R11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Quarnier</surname><given-names>PH</given-names></name><name><surname>Borsboom</surname><given-names>GJ</given-names></name><name><surname>Brunekreff</surname><given-names>B</given-names></name><etal/></person-group><article-title>Spirometric refer-ence values for white European children and adolescents: Polgar revisited</article-title><source>Pediatr Pulmonol</source><year>1995</year><volume>19</volume><fpage>135</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">7659469</pub-id></citation></ref><ref id="R12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Casan</surname><given-names>P</given-names></name><name><surname>Roca</surname><given-names>J</given-names></name><name><surname>Sanchis</surname><given-names>J</given-names></name></person-group><article-title>Spirometric response to a bronchodilator. Reference values for healthy children and adolescents</article-title><source> Bull Eur Physiopathol Respir</source><year>1983</year><volume>19</volume><fpage>567</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">6652262</pub-id></citation></ref><ref id="R13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dales</surname><given-names>RE</given-names></name><name><surname>Spitzer</surname><given-names>WO</given-names></name><name><surname>Tousignant</surname><given-names>P</given-names></name><name><surname>Schechter</surname><given-names>M</given-names></name><name><surname>Suissa</surname><given-names>S</given-names></name></person-group><article-title>Clinical interpretation of airway response to a bronchodilator</article-title><source>Am Rev Respir Dis</source><year>1988</year><volume>138</volume><fpage>317</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">3195831</pub-id></citation></ref><ref id="R14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Juniper</surname><given-names>EF</given-names></name><name><surname>Guyatt</surname><given-names>GH</given-names></name><name><surname>Feeny</surname><given-names>DH</given-names></name><name><surname>Ferrie</surname><given-names>PJ</given-names></name><name><surname>Griffith</surname><given-names>LE</given-names></name><name><surname>Townsend</surname><given-names>M</given-names></name></person-group><article-title>Measuring Quality of Life in children with asthma</article-title><source>Qual Life Res</source><year>1996</year><volume>5</volume><fpage>35</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">8901365</pub-id></citation></ref><ref id="R15"><label>15</label><citation citation-type="journal"><article-title>The Childhood Asthma Management Program Research Group.Long-term effects of budesonide or nedocromil in children with asthma</article-title><source> N Engl J Med</source><year>2000</year><volume>343</volume><fpage>1054</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">11027739</pub-id></citation></ref><ref id="R16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>DM</given-names></name><name><surname>Cutz</surname><given-names>E</given-names></name><name><surname>Levison</surname><given-names>H</given-names></name></person-group><article-title>Occult pulmonary abnormalities in asymptomatic asthmatic children</article-title><source>Chest</source><year>1977</year><volume>71</volume><fpage>361</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">837750</pub-id></citation></ref><ref id="R17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname><given-names>JY</given-names></name><name><surname>Simpson</surname><given-names>H</given-names></name></person-group><article-title>Pulmonary function in severe chronic asthma in children during apparent clinical remission</article-title><source>Eur J Respir Dis</source><year>1983</year><volume>64</volume><fpage>487</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">6628583</pub-id></citation></ref><ref id="R18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferguson</surname><given-names>AC</given-names></name></person-group><article-title>Persisting airway obstruction in asymptomatic children with asthma with normal peak expiratory flow rates</article-title><source>J Allergy Clin Immunol</source><year>1988</year><volume>82</volume><fpage>19</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">3392366</pub-id></citation></ref><ref id="R19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tomita</surname><given-names>K</given-names></name><name><surname>Hanaki</surname><given-names>K</given-names></name><name><surname>Hasegawa</surname><given-names>Y</given-names></name><etal/></person-group><article-title>San-in Asthma Research Group. Underrecognition of the severity of asthma and undertreatment of asthma in a rural area of Japan</article-title><source>J Asthma</source><year>2005</year><volume>42</volume><fpage>689</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">16304712</pub-id></citation></ref><ref id="R20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Warke</surname><given-names>TJ</given-names></name><name><surname>Fitch</surname><given-names>PS</given-names></name><name><surname>Brown</surname><given-names>V</given-names></name><etal/></person-group><article-title>Outgrown asthma does not mean no airways inflammation</article-title><source>Eur Respir J</source><year>2002</year><volume>19</volume><fpage>284</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">11871365</pub-id></citation></ref><ref id="R21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Den Toorn</surname><given-names>LM</given-names></name><name><surname>Prins</surname><given-names>JB</given-names></name><name><surname>Overbeek</surname><given-names>SE</given-names></name><name><surname>Hoogsteden</surname><given-names>HC</given-names></name><name><surname>de Jongste</surname><given-names>JC</given-names></name></person-group><article-title>Adolescents in clinical remission of atopic asthma have elevated exhaled nitric oxide levels and bronchial hyperresponsiveness</article-title><source>Am J Respir Crit Care Med</source><year>2000</year><volume>162</volume><fpage>953</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">10988112</pub-id></citation></ref><ref id="R22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boulet</surname><given-names>LP</given-names></name><name><surname>Turcotte</surname><given-names>H</given-names></name></person-group><article-title>Perception scoring of induced bronchoconstriction as an index of awareness of asthma symptoms</article-title><source>Chest</source><year>1994</year><volume>105</volume><fpage>1430</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">8181331</pub-id></citation></ref><ref id="R23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boulet</surname><given-names>LP</given-names></name></person-group><article-title>Asymptomatic airway hyperresponsiveness. A curiosity or an opportunity to prevent asthma?</article-title><source>Am J Respir Crit Care Med</source><year>2003</year><volume>167</volume><fpage>371</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">12554625</pub-id></citation></ref><ref id="R24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McFadden</surname><given-names>ER</given-names></name><name><surname>Kiser</surname><given-names>R</given-names></name><name><surname>deGroot</surname><given-names>WJ</given-names></name></person-group><article-title>Acute bronchial asthma. Relations between clinical and physiologic manifestations</article-title><source>New Engl J Med</source><year>1973</year><volume>228</volume><fpage>221</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">4682217</pub-id></citation></ref><ref id="R25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koenig</surname><given-names>P</given-names></name><name><surname>Rejent</surname><given-names>A</given-names></name></person-group><article-title>Subjective and objective means of assessing cystic fibrosis and asthma</article-title><source>Ann Allergy</source><year>1982</year><volume>49</volume><fpage>86</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">7103153</pub-id></citation></ref><ref id="R26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Boeck</surname><given-names>C</given-names></name><name><surname>Zinman</surname><given-names>R</given-names></name><name><surname>Larson</surname><given-names>C</given-names></name><name><surname>Fox</surname><given-names>Z</given-names></name></person-group><article-title>Importance of physician identification of airflow limitation in stable asthmatics</article-title><source>Ann Allergy</source><year>1984</year><volume>53</volume><fpage>30</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">6742523</pub-id></citation></ref><ref id="R27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rubinfeld</surname><given-names>AR</given-names></name><name><surname>Pain</surname><given-names>MCF</given-names></name></person-group><article-title>Perception of asthma</article-title><source>Lancet</source><year>1976</year><volume>1</volume><fpage>882</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">58147</pub-id></citation></ref><ref id="R28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Linna</surname><given-names>O</given-names></name></person-group><article-title>Children's ability to identify bronchial obstruction</article-title><source>Acta Paediatr</source><year>1994</year><volume>83</volume><fpage>662</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">7919767</pub-id></citation></ref><ref id="R29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gaustrin</surname><given-names>D</given-names></name><name><surname>Lapierre</surname><given-names>JG</given-names></name><name><surname>Malo</surname><given-names>JL</given-names></name><name><surname>Infante-Rivard</surname><given-names>C</given-names></name></person-group><article-title>Airway hyperresponsiveness and symptoms of asthma in a six-year follow-up study of childhood asthma</article-title><source>Chest</source><year>1999</year><volume>116</volume><fpage>1659</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">10593791</pub-id></citation></ref><ref id="R30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gruffydd-Jones</surname><given-names>K</given-names></name><name><surname>Ward</surname><given-names>S</given-names></name><name><surname>Stonham</surname><given-names>C</given-names></name><name><surname>Macfarlane</surname><given-names>TV</given-names></name><name><surname>Thomas</surname><given-names>M</given-names></name></person-group><article-title>The use of exhaled nitric oxide monitoring in primary care asthma clinics a pilot study</article-title><source> Prim Care Respir J</source><year>2007</year><volume>16</volume><issue>6</issue><fpage>349</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">18157462</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="F1" position="float"><label>Fig. (1)</label><caption><p>Variation in FEV<sub>1</sub> before and after bronchodilation in 15 children who had previously shown a positive bronchodilation (BD) test. The BD test was considered to be positive when variation in FEV<sub>1</sub> at baseline and after bronchodilation, expressed as a percentage of the baseline value, was &#x02265;12%.</p></caption><graphic xlink:href="TORMJ-2-1_F1"/></fig><table-wrap id="T1" position="float"><label>Table 1.</label><caption><p> Main Clinical and Spirometric Characteristics of 134 Children (Mean Age 10.95; 98 Males and 36 Females) Enrolled in the Study </p></caption><table frame="border" rules="all" width="100%"><thead><tr><th colspan="2" rowspan="2"/><th colspan="2" rowspan="1">Under Control (n=98)</th><th rowspan="2" colspan="1">Not Under Control (n=36)</th><th rowspan="2" colspan="1">All Patients n=134</th></tr><tr><th rowspan="1" colspan="1"><italic>Negative Bronchodilation Test (n=81)</italic></th><th rowspan="1" colspan="1"><italic>Positive Bronchodilation Test (n=17)</italic></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="8" colspan="1"><bold>Asthma severity</bold></td><td rowspan="2" align="center" valign="middle" colspan="1"><bold><italic>Intermittent</italic></bold></td><td align="center" rowspan="1" colspan="1"><italic>34 (42%)</italic></td><td align="center" rowspan="1" colspan="1"><italic>7 (41 %)</italic></td><td rowspan="2" align="center" valign="middle" colspan="1">7 (19%)</td><td rowspan="2" align="center" valign="middle" colspan="1">48 (36%)</td></tr><tr><td align="center" colspan="2" rowspan="1"><bold>41 (42%)</bold></td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1"><bold><italic>Mild persistent</italic></bold></td><td align="center" rowspan="1" colspan="1"><italic>40 (50%)</italic></td><td align="center" rowspan="1" colspan="1"><italic>7 (40%)</italic></td><td rowspan="2" align="center" valign="middle" colspan="1">19 (53%)</td><td rowspan="2" align="center" valign="middle" colspan="1">66 (49%)</td></tr><tr><td colspan="2" align="center" rowspan="1"><bold>47 (48%)</bold></td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1"><bold><italic>Moderate persistent</italic></bold></td><td align="center" rowspan="1" colspan="1"><italic>7 (9%)</italic></td><td align="center" rowspan="1" colspan="1"><italic>3 (18%)</italic></td><td rowspan="2" align="center" valign="middle" colspan="1">7 (19%)</td><td rowspan="2" align="center" valign="middle" colspan="1">17 (13%)</td></tr><tr><td colspan="2" align="center" rowspan="1"><bold>10 (10%)</bold></td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1"><bold><italic>Severe persistent</italic></bold></td><td align="center" rowspan="1" colspan="1"><italic>0</italic></td><td align="center" rowspan="1" colspan="1"><italic>0</italic></td><td rowspan="2" align="center" valign="middle" colspan="1">3 (8%)</td><td rowspan="2" align="center" valign="middle" colspan="1">3 (2%)</td></tr><tr><td colspan="2" align="center" rowspan="1"><bold>0</bold></td></tr><tr><td rowspan="6" align="center" valign="middle" colspan="1"><bold>Controller medications</bold></td><td rowspan="2" align="center" valign="middle" colspan="1"><bold><italic>ICS</italic><xref ref-type="table-fn" rid="T1FN1">*</xref></bold></td><td align="center" rowspan="1" colspan="1"><italic>50 (51%)</italic></td><td align="center" rowspan="1" colspan="1"><italic>8 (47%)</italic></td><td rowspan="2" align="center" valign="middle" colspan="1">17 (47%)</td><td rowspan="2" align="center" valign="middle" colspan="1">67 (50%)</td></tr><tr><td colspan="2" align="center" rowspan="1"><bold>42 (52%)</bold></td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1"><bold><italic>ICS</italic><xref ref-type="table-fn" rid="T1FN1">*</xref><italic>+ LABA</italic><xref ref-type="table-fn" rid="T1FN2">&#x02020;</xref></bold></td><td align="center" rowspan="1" colspan="1"><italic>11 (11%)</italic></td><td align="center" rowspan="1" colspan="1"><italic>2 (12%)</italic></td><td rowspan="2" align="center" valign="middle" colspan="1">6 (17%)</td><td rowspan="2" align="center" valign="middle" colspan="1">17 (13%)</td></tr><tr><td colspan="2" align="center" rowspan="1"><bold>9 (11%)</bold></td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1"><bold><italic>Only reliever medications</italic></bold></td><td align="center" rowspan="1" colspan="1"><italic>37 (38%)</italic></td><td align="center" rowspan="1" colspan="1"><italic>7 (41%)</italic></td><td rowspan="2" align="center" valign="middle" colspan="1">13 (36%)</td><td rowspan="2" align="center" valign="middle" colspan="1">50 (37%)</td></tr><tr><td colspan="2" align="center" rowspan="1"><bold>30 (37%)</bold></td></tr></tbody></table><table-wrap-foot><fn id="T1FN1"><label>*</label><p>ICS: inhaled corticosteroids;</p></fn><fn id="T1FN2"><label>&#x02020;</label><p>LABA: long-acting &#x003b2;<sub>2</sub>agonists; bronchodilation test was considered to be positive when deltaFEV<sub>1</sub>&#x02265;12%; deltaFEV<sub>1</sub>= (FEV<sub>1</sub>postBD-FEV<sub>1</sub>at baseline) / FEV<sub>1</sub> at baseline.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2 .</label><caption><p>Results of Spirometry, Bronchodilation Test, Skin Prick Test and PAQLQ Scores</p></caption><table frame="border" rules="all" width="100%"><thead><tr><th colspan="2" rowspan="2"/><th colspan="2" rowspan="1">Under Control (n=98)</th><th rowspan="2" colspan="1">Not Under Control n=36</th><th rowspan="2" colspan="1">All Patients n=134</th></tr><tr><th rowspan="1" colspan="1"><italic>Negative Bronchodilation Test (n=81)</italic></th><th rowspan="1" colspan="1"><italic>Positive Bronchodilation Test (n=17)</italic></th></tr></thead><tbody><tr><td colspan="2" rowspan="2" align="center" valign="middle"><bold>Mean FVC &#x000b1; SD</bold></td><td align="center" rowspan="1" colspan="1"><italic>106.% &#x000b1; 13.5%</italic></td><td align="center" rowspan="1" colspan="1"><italic>110%&#x000b1;15%</italic></td><td rowspan="2" align="center" valign="middle" colspan="1">99%&#x000b1;16</td><td rowspan="2" align="center" valign="middle" colspan="1">105%&#x000b1;15%</td></tr><tr><td colspan="2" align="center" rowspan="1"><bold>107%&#x000b1;14%</bold></td></tr><tr><td colspan="2" rowspan="2" align="center" valign="middle"><bold>Mean FEV<sub>1 </sub>&#x000b1; SD</bold></td><td align="center" rowspan="1" colspan="1"><italic>99%&#x000b1; 12% </italic><bold>&#x000a7;</bold></td><td align="center" rowspan="1" colspan="1"><italic>92%&#x000b1;10% </italic><bold>&#x000a7;</bold></td><td rowspan="2" align="center" valign="middle" colspan="1">85%&#x000b1;20 $</td><td rowspan="2" align="center" valign="middle" colspan="1">94%&#x000b1; 15.5%</td></tr><tr><td colspan="2" align="center" rowspan="1"><bold>97%&#x000b1;18% </bold>$</td></tr><tr><td colspan="2" rowspan="2" align="center" valign="middle"><bold>Mean FEV<sub>1</sub>/FVC &#x000b1; SD</bold></td><td align="center" rowspan="1" colspan="1"><italic>94%&#x000b1;9.6% </italic><bold>#</bold></td><td align="center" rowspan="1" colspan="1"><italic>84%&#x000b1;11% </italic><bold>#</bold></td><td rowspan="2" align="center" valign="middle" colspan="1">85.05%&#x000b1; 13 &#x000a5;</td><td rowspan="2" align="center" valign="middle" colspan="1">90%&#x000b1; 12%</td></tr><tr><td colspan="2" align="center" rowspan="1"><bold>92%&#x000b1;10.5% </bold>&#x000a5;</td></tr><tr><td colspan="2" rowspan="2" align="center" valign="middle"><bold>Delta FEV<sub>1</sub><xref ref-type="table-fn" rid="T2FN2">*</xref>&#x02265;12%</bold></td><td align="center" rowspan="1" colspan="1"><italic>0</italic></td><td align="center" rowspan="1" colspan="1"><italic>17 (100%)</italic></td><td rowspan="2" align="center" valign="middle" colspan="1">17(47%)</td><td rowspan="2" align="center" valign="middle" colspan="1">34(25%)</td></tr><tr><td colspan="2" align="center" rowspan="1"><bold>17 (17%)</bold></td></tr><tr><td rowspan="6" align="center" valign="middle" colspan="1"><bold>SPT<xref ref-type="table-fn" rid="T2FN3">&#x02020;</xref> positive results</bold></td><td rowspan="2" align="center" valign="middle" colspan="1"><bold><italic>Grass pollens</italic></bold></td><td align="center" rowspan="1" colspan="1"><italic>85(87%)</italic></td><td align="center" rowspan="1" colspan="1"><italic>14 (82%)</italic></td><td rowspan="2" align="center" valign="middle" colspan="1">32(89%)</td><td rowspan="2" align="center" valign="middle" colspan="1">117(87%)</td></tr><tr><td colspan="2" align="center" rowspan="1"><bold>71 (88%)</bold></td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1"><bold><italic>House dust mites</italic></bold></td><td align="center" rowspan="1" colspan="1"><italic>41 (42%)</italic></td><td align="center" rowspan="1" colspan="1"><italic>5(29%)</italic></td><td rowspan="2" align="center" valign="middle" colspan="1">19(53%)</td><td rowspan="2" align="center" valign="middle" colspan="1">60(45%)</td></tr><tr><td colspan="2" align="center" rowspan="1"><bold>36 (44%)</bold></td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1"><bold><italic>Cat dander</italic></bold></td><td align="center" rowspan="1" colspan="1"><italic>35 (36%)</italic></td><td align="center" rowspan="1" colspan="1"><italic>4(23.5%)</italic></td><td rowspan="2" align="center" valign="middle" colspan="1">15(42%)</td><td rowspan="2" align="center" valign="middle" colspan="1">50(37%)</td></tr><tr><td colspan="2" align="center" rowspan="1"><bold>31 (38%)</bold></td></tr><tr><td colspan="2" rowspan="2" align="center" valign="middle"><bold>Mean PAQLQ<xref ref-type="table-fn" rid="T2FN4">&#x02021;</xref> score &#x000b1; SD</bold></td><td align="center" rowspan="1" colspan="1"><italic>6.18&#x000b1;0.75</italic></td><td align="center" rowspan="1" colspan="1"><italic>6.43&#x000b1;0.52</italic></td><td rowspan="2" align="center" valign="middle" colspan="1">5.42 &#x000b1;1.18</td><td rowspan="2" align="center" valign="middle" colspan="1">6.02&#x000b1;0.93</td></tr><tr><td colspan="2" align="center" rowspan="1"><bold>6.23&#x000b1;0.72</bold></td></tr></tbody></table><table-wrap-foot><fn id="T2FN1"><p>Spirometric data are expressed as percentage of predicted. Statistics showed significant statistical differences in FEV<sub>1</sub>and in FEV<sub>1</sub>/FVC between children with apparently under control asthma and with not-controlled asthma ($: p&#x02264;0.001 and &#x000a5;: p&#x02264;0.005 respectively) and between children with under control asthma and a negative or positive response to bronchodilation (&#x000a7;: p&#x02264;0.05 and #: p&#x02264;0.01 respectively).</p></fn><fn id="T2FN2"><label>*</label><p>deltaFEV1= (FEV1 post bronchodilation &#x02013; FEV1 at baseline) / FEV1 at baseline;</p></fn><fn id="T2FN3"><label>&#x02020;</label><p>SPT: Skin Prick Test;</p></fn><fn id="T2FN4"><label>&#x02021;</label><p>PAQLQ: Pediatric Asthma Quality of Life Questionnaire.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table 3.</label><caption><p>Main Allergic Characteristics of 134 Children Included in Our Study</p></caption><table frame="border" rules="all" width="100%"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Grass Pollens</th><th rowspan="1" colspan="1">House Dust Mites</th><th rowspan="1" colspan="1">Cat Dander</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Under control, negative bronchodilation test (n=81)</td><td align="center" rowspan="1" colspan="1">72 (88.9%)</td><td align="center" rowspan="1" colspan="1">36 (44.4%)</td><td align="center" rowspan="1" colspan="1">31 (38.3%)</td></tr><tr><td align="center" rowspan="1" colspan="1">Under control, positive bronchodilation test (n=17)</td><td align="center" rowspan="1" colspan="1">14 (82.4%)</td><td align="center" rowspan="1" colspan="1">5 (29.4%)</td><td align="center" rowspan="1" colspan="1">4 (23.5%)</td></tr><tr><td align="center" rowspan="1" colspan="1">Not under control (n=36)</td><td align="center" rowspan="1" colspan="1">32 (88.9%)</td><td align="center" rowspan="1" colspan="1">19 (52.8%)</td><td align="center" rowspan="1" colspan="1">15 (41.7%)</td></tr></tbody></table><table-wrap-foot><fn id="T3FN1"><p>No differences between the three groups are statistically significant.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" position="float"><label>Table 4.</label><caption><p>Spirometric Values and PAQLQ Scores at the First Visit in the Two Subgroups of Patients with Positive Bronchodilation Test (n=17) who had an Adjustment in their Asthma Therapy (First Group; n= 8), Consisting of the Introduction of or Increase in Inhaled Corticosteroids (ICS), and who had No Adjustment in their Therapy (Second Group; n=9)</p></caption><table frame="border" rules="all" width="100%"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Patients with Adjustment in Therapy (n=8)</th><th rowspan="1" colspan="1">Patients without Adjustment in Therapy (n=9)</th><th rowspan="1" colspan="1">All Patients with Positive Bronchodilation Test (n=17)</th><th rowspan="1" colspan="1">p Value</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1"><bold>Mean FVC &#x000b1; SD</bold></td><td align="center" rowspan="1" colspan="1">107%&#x000b1;15%</td><td align="center" rowspan="1" colspan="1">112%&#x000b1;14%</td><td align="center" rowspan="1" colspan="1">110%&#x000b1; 15%</td><td align="center" rowspan="1" colspan="1">0.475</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>Mean FEV<sub>1 </sub>&#x000b1; SD</bold></td><td align="center" rowspan="1" colspan="1">91%&#x000b1;10%</td><td align="center" rowspan="1" colspan="1">92%&#x000b1;10%</td><td align="center" rowspan="1" colspan="1">92%	&#x000b1;10%</td><td align="center" rowspan="1" colspan="1">0.840</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>Mean FEV<sub>1</sub>/FVC &#x000b1; SD</bold></td><td align="center" rowspan="1" colspan="1">86%&#x000b1;12%</td><td align="center" rowspan="1" colspan="1">82%&#x000b1;10%</td><td align="center" rowspan="1" colspan="1">84%	&#x000b1;11%</td><td align="center" rowspan="1" colspan="1">0.465</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>Mean Delta FEV<sub>1</sub><xref ref-type="table-fn" rid="T4FN2">*</xref>&#x000b1; SD</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">19%&#x000b1;6%</td><td align="center" valign="middle" rowspan="1" colspan="1">16%&#x000b1;6%</td><td align="center" valign="middle" rowspan="1" colspan="1">17.5%&#x000b1;6%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.320</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>Mean PAQLQ<xref ref-type="table-fn" rid="T4FN3">&#x02021;</xref>score &#x000b1; SD</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">6.48&#x000b1;0.79</td><td align="center" valign="middle" rowspan="1" colspan="1">6.73&#x000b1;0.55</td><td align="center" valign="middle" rowspan="1" colspan="1">6.43&#x000b1;0.52</td><td align="center" valign="middle" rowspan="1" colspan="1">0.456</td></tr></tbody></table><table-wrap-foot><fn id="T4FN1"><p>No differences between the two groups are statistically significant</p></fn><fn id="T4FN2"><label>*</label><p>Delta FEV<sub>1</sub> = (FEV<sub>1</sub> post bronchodilation &#x02013; FEV<sub>1</sub> at vaseline) / FEV<sub>1</sub> at baseline;</p></fn><fn id="T4FN3"><label>&#x02021;</label><p>PAQLQ: Pediatric Asthma Quality of Life Questionnaire.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article>





